Parabilis Medicines (NASDAQ:PBLS) Shares Up 7% – Should You Buy?

Posted by George Bondi on Oct 12th, 2026

Parabilis Medicines, Inc. (NASDAQ:PBLS – Get Free Report) shot up 7% on Monday. The company traded as high as $29.50 and last traded at $29.39. 514,173 shares traded hands during mid-day trading, a decline of 31% from the average session volume of 741,096 shares. The stock had previously closed at $27.48.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Lifesci Capital upgraded Parabilis Medicines to a “strong-buy” rating in a research report on Monday, July 6th. Wall Street Zen upgraded shares of Parabilis Medicines to a “hold” rating in a research report on Saturday, June 20th. Guggenheim started coverage on shares of Parabilis Medicines in a report on Monday, July 6th. They set a “buy” rating and a $40.00 price objective on the stock. Weiss Ratings downgraded shares of Parabilis Medicines from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, October 2nd. Finally, Bank of America assumed coverage on shares of Parabilis Medicines in a research report on Monday, July 6th. They issued a “buy” rating and a $45.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $41.67.

Check Out Our Latest Stock Analysis on PBLS

Parabilis Medicines Trading Up 6.8%

The stock has a market capitalization of $3.62 billion and a price-to-earnings ratio of -13.77. The company’s fifty day moving average is $36.11.

Parabilis Medicines (NASDAQ:PBLS – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($2.16). The firm had revenue of $0.15 million during the quarter. As a group, equities research analysts anticipate that Parabilis Medicines, Inc. will post -3.09 EPS for the current year.

Institutional Investors Weigh In On Parabilis Medicines

Several institutional investors and hedge funds have recently added to or reduced their stakes in PBLS. Persistent Asset Partners Ltd acquired a new stake in shares of Parabilis Medicines in the second quarter valued at about $113,000. Alyeska Investment Group L.P. acquired a new stake in Parabilis Medicines in the 2nd quarter valued at about $274,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Parabilis Medicines in the 2nd quarter worth approximately $526,000. WINTON GROUP Ltd purchased a new position in Parabilis Medicines in the 2nd quarter worth approximately $955,000. Finally, Squarepoint Ops LLC purchased a new position in Parabilis Medicines in the 2nd quarter worth approximately $1,327,000.